NCT07137494 - A Study of MB-CART19.1 Cellular Therapy for People With Central Nervous System Lymphoma (CNSL) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 14, 2025

Primary Completion Date

August 31, 2028

Study Completion Date

August 31, 2028

Conditions

Primary Central Nervous System (CNS) LymphomaSecondary Central Nervous System Lymphoma

Interventions

BIOLOGICAL

MB-CART19.1 Cellular Therapy

MB-CART19.1 will be infused as a single infusion during an inpatient admission.

Trial Locations (1)

RECRUITING

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York